FTSE MIB
33.926,31 -344,81 (-1,01%) Dow Jones
37.806,92 -654,00 (-1,70%) Nasdaq
15.449,16 -263,59 (-1,68%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,14 -0,67 (-0,81%) Bitcoin EUR
59.198,00 -1.560,09 (-2,57%)
Immunocore Holdings plc (IMCR)
| Chiusura precedente | 58,47 |
| Aperto | 57,34 |
| Denaro | 57,84 x 100 |
| Lettera | 58,33 x 200 |
| Min-Max giorno | 57,34 - 58,37 |
| Intervallo di 52 settimane | 42,21 - 76,98 |
| Volume | |
| Media Volume | 504.179 |
| Capitalizzazione | 2,829B |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,41 |
| Prossima data utili | 08 mag 2024 - 12 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 86,07 |
GlobeNewswireImmunocore announces upcoming presentation and posters at ESMO 2023
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 07 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor co
- GlobeNewswire
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024 Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expans
